CDKN2A and melanoma: More recent reports showed biallelic deletion in ∼45% of melanoma metastases, supporting the role of this locus in melanoma progression (Grafstrom et al.,2005) and we have shown that epigenetic silencing of P14ARF is also common in metastatic disease (Freedberg et al.,2008).